S. 2912 · 114th Congress
Trickett Wendler Right to Try Act of 2016
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 114th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
JohnsonSponsor43 cosponsors · 2 D, 40 R, 1 I
R
Blunt
JF
R
Flake
OH
R
Hatch
JI
R
Inhofe
JI
R
Isakson
JM
R
McCain
LM
R
Murkowski
DP
R
Perdue
SC
R
Capito
BC
R
Corker
TC
R
Cotton
LG
R
Graham
CG
R
Grassley
MR
R
Rubio
JS
R
Sessions
TT
R
Tillis
JR
R
Risch
JB
R
Boozman
PT
R
Toomey
DV
R
Vitter
JB
R
Barrasso
DC
R
Coats
DS
R
Sullivan
TC
R
Cruz
ME
R
Enzi
RW
R
Wicker
SD
R
Daines
TC
R
Cochran
MC
R
Crapo
DH
R
Heller
JH
R
Hoeven
JL
R
Lankford
MM
R
McConnell
JM
R
Moran
JM
D
Manchin
PR
R
Roberts
MR
R
Rounds
RS
R
Shelby
JD
D
Donnelly
CG
R
Gardner
RP
R
Paul
BS
R
Sasse
AK
I
King0 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill bars the federal government from prohibiting or restricting the production, manufacture, distribution, prescribing, or dispensing of an experimental drug, biological product, or device that is: (1) intended to treat a patient who has been diagnosed with a terminal illness; and (2) authorized by, and in accordance with, state law.
What it does: CRS summary · Introduced in Senate · May 10, 2016
Trickett Wendler Right to Try Act of 2016
This bill bars the federal government from prohibiting or restricting the production, manufacture, distribution, prescribing, or dispensing of an experimental drug, biological product, or device that is: (1) intended to treat a patient who has been diagnosed with a terminal illness; and (2) authorized by, and in accordance with, state law. The federal government may not restrict the possession or use of such a treatment by a patient certified by a physician as having exhausted all other treatment options.
A producer, manufacturer, distributor, prescriber, dispenser, possessor, or user of such a treatment has no liability regarding the treatment.
The outcome of production, manufacture, distribution, prescribing, dispensing, possession, or use of such a treatment may not be used by a federal agency to adversely impact review or approval of the treatment.
The treatment must: (1) have successfully completed a phase 1 (initial, small scale) clinical trial; (2) remain under investigation in a clinical trial approved by the Food and Drug Administration (FDA); and (3) not be approved, licensed, or cleared for sale under the Federal Food, Drug, or Cosmetic Act or the Public Health Service Act.
Not later than 30 days after enactment of this bill, and every 30 days thereafter until implementation is complete, the FDA must report on its progress in implementing a streamlined application process for compassionate use of experimental drugs and biological products.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Trickett Wendler Right to Try Act of 2016
Latest action (Sep 22, 2016): Committee on Homeland Security and Governmental Affairs. Hearings held.
Policy area: Health · Origin: Senate · Introduced: May 10, 2016
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.